Clinical Trials Browser

INDUSTRY × Standard of Care × 1 year × Clear all

Hematologic Neoplasms

Breast Neoplasms

Progressive Metastatic Castrate Resistant Prostate Cancer

Neoplasms, Colorectal Neoplasms

Breast Neoplasms

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

Skin Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Prostatic Neoplasms

Prostatic Neoplasms

Glioblastoma

Advanced/Metastatic Solid Tumors

Ovarian Neoplasms

Prostatic Neoplasms

Multiple Myeloma

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Advanced Cancer

Multiple Myeloma

Lymphoma, Non-Hodgkin, Recurrence

Multiple Myeloma, Neoplasms, Plasma Cell

Clinical Trials

MK-3475-587

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

DARE

TulmiSTAR-01

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

ELENI

DALY 2-EU

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Orca-T

AcTFirst

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

FIRST

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

EMERALD

Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

MATTERS

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

TRANSFORM

ASTEROID 6

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US